Skip to content
general-news — Truth — Health — Medical-conditions — Health-and-wellness — War-and-conflicts — Politics — Science

Trump Issues Executive Decree to Disengage from the World Health Organization

Leaving the WHO by Dylan Eleven: Is it a definitive break from pharmaceutical influence? However, it does not necessarily signify this change.

,   and  Administrator
3 min read
departing from WHO: potential reduction in pharmaceutical control; however, complete reversal...
departing from WHO: potential reduction in pharmaceutical control; however, complete reversal remains uncertain

Trump Issues Executive Decree to Disengage from the World Health Organization

Trump's Drastic Move Against Biopharma Domination

Let's dive into the exciting news that has the Biopharmaceutical Complex shaking in their boots: the U.S. pulling out of the WHO! This isn't just any old move, it's a powerful blow to the Biopharma Complex's bid for control over plants, humans, animals, and the environment via their 'One Health approach'. And even if an overreaching 'pandemic treaty' gets passed, it won't affect America.

Here's the breakdown:

Executive Order:

January 20, 2025 - The White House

By revoking Biden's EO (which probably wasn't even real) and pulling out of the WHO, Trump's new Executive Order targets the Biopharma Complex square on, taking aim at their mishandling of the COVID-19 pandemic and other global health crises. The order also addresses their failure to implement necessary reforms, their inability to demonstrate independence from member states' inappropriate political influence, and their outrageous demands for overly onerous payments from the U.S., while China and other countries contribute significantly less.

What's Next?

The U.S. will likely pause its funding, support, and resources to the WHO. United States Government personnel or contractors working for the WHO will be recalled and re-assigned. The Director of the White House Office of Pandemic Preparedness and Response Policy will review, rescind, and replace the United States' Global Health Security Strategy as soon as possible.

The withdrawal process will take effect on January 22, 2026, as per the WHO's rules and the U.S. notification to the UN. The U.S. has yet to pay its WHO membership fees for 2025, totaling $260 million.

Implications for the Biopharmaceutical Complex:

  • Impact on Global Health Initiatives: The U.S. withdrawal could affect partnerships and collaborations with the biopharmaceutical industry, potentially limiting the industry's access to new markets and slowing down the development of new treatments.
  • Regulatory and Research Implications: The biopharma complex will likely face challenges engaging in global research collaborations and may experience a reduction in their industry's ability to participate in international regulatory standards.
  • Economic and Political Implications: Economic and political tensions between the U.S. and the biopharmaceutical industry could arise due to funding fluctuations, regulatory changes, and shifts in market opportunities.

Keep your eyes peeled as this developing story unfolds. The Biopharmaceutical Complex may have met their match in Trump's Executive Order!

Source: www.mcculloughfnd.orgSource: www.thelibertybeacon.comRelated:

  • Effects on the Relationship Between the U.S. and the Biopharmaceutical Complex (In-depth analysis on the economic, regulatory, and political implications)
  • Global System Negotiations (Exploring the possibility of the U.S. negotiating a new approach to worldwide health policies)
  • U.S. Global Health Security Strategy Update (Providing information on the United States' updated global health security strategy following the U.S. withdrawal from the WHO)
  1. The drastic move by Trump, pulling out of the World Health Organization (WHO), could have significant implications for the biopharmaceutical complex, particularly in relation to truthful information dissemination about health-and-wellness, medical-conditions, and policy-and-legislation concerning health crises.
  2. In the realm of politics and general news, the withdrawal from the WHO could instigate war-and-conflicts with the biopharmaceutical industry, potentially due to economic factors such as funding fluctuations and regulatory changes, or shifts in market opportunities.
  3. Science, in the context of health research and development, might face challenges as the biopharmaceutical complex experiences restrictions in global collaborations, which could slow the discovery of new treatments and advancements.
  4. As the withdrawal process unfolds, it's crucial to consider the health impacts on both humans and the environment, given that the Biopharmaceutical Complex has been propagating the One Health approach. This could further complicate the discourse about truth, health, and environmental sustainability in the years to come.

Read also:

    Related

    Latest